Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;64(8):882-889.
doi: 10.1111/myc.13294. Epub 2021 May 9.

Rhinofacial conidiobolomycosis: Clinical and microbiological characterisation and shift in the management of a rare disease

Lalee Varghese  1 , Regi Kurien  1 , Rani Diana Sahni  2 , Abi Manesh  3 , Lisa Mary Cherian  1 , Dincy Peter  4 , Divya Dayanand  3 , Joy Sarojini Michael  2 , Meera Thomas  5 , V Rupa  1 , Susanne Pulimood  4 , George M Varghese  3
Affiliations

Rhinofacial conidiobolomycosis: Clinical and microbiological characterisation and shift in the management of a rare disease

Lalee Varghese et al. Mycoses. 2021 Aug.

Abstract

Background: Conidiobolomycosis is a rare tropical rhinofacial fungal infection which has not been well characterised. The available evidence in its management is sparse due to lack of clinical studies and the limited data on antifungal susceptibility patterns.

Objective: To analyse the clinical manifestations, antifungal treatment and outcomes of patients with conidiobolomycosis and to determine antifungal susceptibility profiles of the isolates.

Patients/methods: Retrospective analysis of data of all patients with a diagnosis of conidiobolomycosis confirmed by histopathology and culture at a tertiary care hospital from 2012 to 2019 was done.

Results: There were 22 patients, 21 males and one female, with a mean age of 37.1 years. Most common presenting symptom was nasal obstruction, found in 20 (90.90%) patients. Patients who presented within 12 months had a better cure rate (85%) compared to those who presented late (67%). Among the 19 patients who had a follow-up, good outcome was seen in 15 of the 17 (88.24%) patients who were on itraconazole or potassium iodide containing regimen. Of the six patients who received additional trimethoprim-sulphamethoxazole (co-trimoxazole), 67% showed good outcome with two patients showing complete cure and two patients still on treatment with significant improvement. High minimum inhibitory concentration (MIC) values were noted for azoles and amphotericin B, whereas co-trimoxazole showed lowest MIC ranges.

Conclusion: Itraconazole and potassium iodide are reasonable first-line options for the treatment of conidiobolomycosis. Good clinical response to KI and comparatively lower MIC of co-trimoxazole are promising. Further studies are required for developing clinical breakpoints that can predict therapeutic outcomes.

Keywords: antifungal agents; antifungal susceptibility; co-trimoxazole; conidiobolomycosis; potassium iodide; sinonasal infection.

PubMed Disclaimer

References

REFERENCES

    1. Vilela R, Mendoza L. Human pathogenic entomophthorales. Clin Microbiol Rev [Internet]. 2018;31:e00014-18.
    1. Gupta N, Kumar R, Ramteke P, Soneja M. Look before you leap: a case series of conidiobolomycosis from the Indian subcontinent. J Family Med Prim Care. 2018;7:1113.
    1. Arora N, Bhargava EK, Rai V. Nasal conidiobolomycosis- the unknown threat. J Clin Diagn Res. 2016;10:MJ01.
    1. Gupta M, Narang T, Kaur RJ, Manhas A, Saikia UN, Dogra S. A prospective case series evaluating efficacy and safety of combination of itraconazole and potassium iodide in rhinofacial conidiobolomycosis. Int J Dermatol. 2016;55:208-214.
    1. Michael RC, Michael JS, Mathews MS, Rupa V. Unusual presentation of entomophthoromycosis. Indian J Med Microbiol. 2009;27:156.

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources